Tumor-Associated Macrophages: Key Players in the Non-Small Cell Lung Cancer Tumor Microenvironment

被引:0
|
作者
Lv, Tongtong [1 ,2 ]
Fan, Rui [1 ]
Wu, Jiaqi [1 ,2 ]
Gong, Haolan [1 ]
Gao, Xiaoru [1 ]
Liu, Xin [1 ]
Gong, Yixin [1 ]
Luo, Bo [3 ]
Zhang, Yanhua [1 ,2 ]
Peng, Xiaochun [1 ,2 ]
Liang, Gai [3 ]
机构
[1] Yangtze Univ, Dept Hematol, Affiliated Hosp 1, Jingzhou, Peoples R China
[2] Yangtze Univ, Hlth Sci Ctr, Sch Basic Med, Dept Pathophysiol, Jingzhou, Peoples R China
[3] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Radiat Oncol, Wuhan, Peoples R China
来源
CANCER MEDICINE | 2025年 / 14卷 / 03期
关键词
biomarkers; drug resistance; NSCLC; TAMs; treatment; PANCREATIC-CANCER; RESISTANCE; EXPRESSION; POLARIZATION; GROWTH; NSCLC; GENE; ADENOCARCINOMA; METASTASIS; MECHANISM;
D O I
10.1002/cam4.70670
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundLung cancer is among the most common and deadliest malignant tumors worldwide. It is often detected at late stages, resulting in unfavorable outcomes, with tumor cell heterogeneity and medication resistance. Tumor-associated macrophages are among the key cells contributing to cancer progression. They are categorized into two primary phenotypes: Proinflammatory (M1) and anti-inflammatory (M2) which are involved in the onset and progression of NSCLC. The role of common cytokines secreted by macrophages in the progression of lung cancer are described, and the effects of various substances such as RNA or protein on the differentiation and polarization of two phenotypes of macrophages are highlighted to characterize the impact of the immune state of tumors on therapeutic effect of treatments and patient prognosis. Researchers have primarily aimed to investigate innovative carriers and strategies based on macrophages to modify the tumor microenvironment. ObjectivesThese approaches are often integrated with other treatments, particularly immunotherapy, to enhance therapeutic efficacy. MethodsA comprehensive review was carried out by systematically synthesizing existing literature on PubMed, using the combination of the keywords "TAMs", "NSCLC", "Drug resistance", and "therapy". The available studies were screened for selection based on quality and relevance. ConclusionsTAMs promote tumor invasion, growth, and metastasis by promoting angiogenesis and EMT. In addition, they contribute to the development of drug resistance and the immunosuppressive microenvironment establishment. The immunosuppressive factors secreted by TAM can weaken the activity of immune cells, inhibit their killing effect on tumors, leading to immune suppression and hindering the effectiveness of treatment. Therefore, TAM is a key target for the development of cancer immunotherapy. Various strategies are being explored, including reducing the recruitment of TAMs and influencing their polarization to treat NSCLC. In addition, TAMs based treatment systems can achieve precise delivery of drugs or gene interfering molecules without causing side effects.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] New Insight of Tumor Microenvironment in Non-Small Cell Lung Cancer
    Sever, Tolga
    Leblebici, Asim
    Koc, Altug
    Binicier, Cilem
    Olgun, Aybuke
    Edizer, Deniz Tuna
    Ozdemir, Taha Resid
    Serin, Gurdeniz
    Erdem, Melek
    Basbinar, Yasemin
    JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES, 2019, 3 (02): : 113 - 120
  • [22] The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time
    Ma, Junliang
    Liu, Lunxu
    Che, Guowei
    Yu, Nanbin
    Dai, Fuqiang
    You, Zongbing
    BMC CANCER, 2010, 10
  • [23] PLGF regulates crosstalk between non-small cell lung cancer cells and tumor-associated macrophages in cancer vascularization and growth
    Zhang, W.
    Lou, Y.
    Yan, B.
    Zhao, Y.
    Cui, S.
    Jiang, L.
    Han, B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Mechanism of TCF21 Downregulation Leading to Immunosuppression of Tumor-Associated Macrophages in Non-Small Cell Lung Cancer
    Liu, Hong
    He, Run
    Yang, Xuliang
    Huang, Bo
    Liu, Hongxiang
    PHARMACEUTICS, 2023, 15 (09)
  • [25] Differentiation-related genes in tumor-associated macrophages as potential prognostic biomarkers in non-small cell lung cancer
    Li, Zhaoxun
    Zhou, Bin
    Zhu, Xinsheng
    Yang, Fujun
    Jin, Kaiqi
    Dai, Jie
    Zhu, Yuming
    Song, Xiao
    Jiang, Gening
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [26] Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects
    Cheng, Daoan
    Ge, Kele
    Yao, Xue
    Wang, Banglu
    Chen, Rui
    Zhao, Weiqing
    Fang, Cheng
    Ji, Mei
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [27] Tumor-associated macrophages promote tumor metastasis via the TGF-β/SOX9 axis in non-small cell lung cancer
    Zhang, Shuai
    Che, Dehai
    Yang, Fang
    Chi, Chunling
    Meng, Hongxue
    Shen, Jing
    Qi, Li
    Liu, Fang
    Lv, Liyan
    Li, Yue
    Meng, Qingwei
    Liu, Junning
    Shang, Lihua
    Yu, Yan
    ONCOTARGET, 2017, 8 (59) : 99801 - 99815
  • [28] Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small Cell Lung Carcinoma
    Zheng, Xiang
    Weigert, Andreas
    Reu, Simone
    Guenther, Stefan
    Mansouri, Siavash
    Bassaly, Birgit
    Gattenlohner, Stefan
    Grimminger, Friedrich
    Pullamsetti, Soni Savai
    Seeger, Werner
    Winter, Hauke
    Savai, Rajkumar
    CANCER RESEARCH, 2020, 80 (20) : 4414 - 4425
  • [29] M2 tumor-associated macrophages promote tumor progression in non-small-cell lung cancer
    Sumitomo, Ryota
    Hirai, Tatsuya
    Fujita, Masaaki
    Murakami, Hiroaki
    Otake, Yosuke
    Huang, Cheng-Long
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (06) : 4490 - 4498
  • [30] Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment
    Kim, Jaehong
    Bae, Jong-Sup
    MEDIATORS OF INFLAMMATION, 2016, 2016